HRP20191965T1 - Stabilizirani polipeptidi faktora rasta slični inzulinu - Google Patents
Stabilizirani polipeptidi faktora rasta slični inzulinu Download PDFInfo
- Publication number
- HRP20191965T1 HRP20191965T1 HRP20191965TT HRP20191965T HRP20191965T1 HR P20191965 T1 HRP20191965 T1 HR P20191965T1 HR P20191965T T HRP20191965T T HR P20191965TT HR P20191965 T HRP20191965 T HR P20191965T HR P20191965 T1 HRP20191965 T1 HR P20191965T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- deleted
- substituted
- mutated
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (9)
1. Polipeptid koji sadrži ljudski IGF-1 protein, naznačen time, što je aminokiselina glicin na položaju 42 navedenog proteina IGF-1 mutirana u serin, te pri čemu numeriranje aminokiselina navedenog ljudskog proteina IGF-1 odgovara SEQ ID NO.: 1.
2. Polipeptid prema patentnom zahtjevu 1, naznačen time, što ljudski protein IGF-1 sadrži slijedeće modifikacije:
a. aminokiselina E3 je izbrisana,
b. aminokiselina G42 je mutirana u serin, i
c. aminokiselina R37 je mutirana u alanin.
3. Polipeptid prema patentnom zahtjevu 1, naznačen time što ljudski protein IGF-1 sadrži slijedeće modifikacije:
a. aminokiseline G1, P2 i E3 su izbrisane,
b. aminokiselina G42 je mutirana u serin, i
c. aminokiselina R37 je mutirana u alanin.
4. Polipeptid prema patentnom zahtjevu 1, naznačen time, što ljudski protein IGF-1 sadrži slijedeće modifikacije:
a. aminokiseline G1, P2 i E3 su izbrisane,
b. aminokiselina G42 je mutirana u serin,
c. aminokiselina R36 je mutirana u glutamin, i
d. aminokiselina R37 je mutirana u alanin.
5. Ljudski protein IGF-1, naznačen time, što je aminokiselina glicin na položaju 42 supstituirana s aminokiselinom serinom i pri čemu aminokiseline:
(a) G1, P2, E3 su izbrisane i aminokiselina R36 je supstituirana ili izbrisana; ili
(b) G1, P2, E3 su izbrisane i aminokiselina R36 je supstituirana s glutaminom (Q); ili
(c) G1, P2, E3 su izbrisane i aminokiselina R37 je supstituirana ili izbrisana; ili
(d) G1, P2, E3 su izbrisane i aminokiselina R37 je supstituirana s glutaminskom kiselinom (E); ili
(e) G1, P2, E3 su izbrisane i aminokiselina R37 je supstituirana s alaninom; ili
(f) G1, P2, E3 su izbrisane i aminokiselina R37 je supstituirana s prolinom (P); ili
(g) G1, P2, E3 su izbrisane i aminokiseline R36 i R37 su supstituirane ili izbrisane; ili
(h) G1, P2, E3 su izbrisane i obje aminokiseline R36 i R37 su supstituirane s glutaminom (Q); ili
(i) G1, P2, E3 su izbrisane i aminokiselina R36 je supstituirana s glutaminom (Q) i R37 je supstituirana s alaninom.
6. Polinukleotid, naznačen time, što sadrži molekulu nukleinske kiselina koja kodira polipeptid prema bilo kojem od patentnih zahtjeva 1-5.
7. Farmaceutski pripravak, naznačen time, što sadrži polipeptid prema bilo kojem od patentnih zahtjeva 1-5, i upotrebljava se u terapiji.
8. Farmaceutski pripravak prema patentnom zahtjevu 7, naznačen time, što je za uporabu u liječenju mišićnog poremećaja kod pacijenta kojem je to potrebno.
9. Farmaceutski pripravak prema patentnom zahtjevu 8, naznačen time, što je mišićni poremećaj, mišićna atrofija.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261738475P | 2012-12-18 | 2012-12-18 | |
| EP13828987.1A EP2935320B1 (en) | 2012-12-18 | 2013-12-16 | Stabilized insulin-like growth factor polypeptides |
| PCT/IB2013/060985 WO2014097116A1 (en) | 2012-12-18 | 2013-12-16 | Stabilized insulin-like growth factor polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191965T1 true HRP20191965T1 (hr) | 2020-01-24 |
Family
ID=50073229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191965TT HRP20191965T1 (hr) | 2012-12-18 | 2013-12-16 | Stabilizirani polipeptidi faktora rasta slični inzulinu |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US10167329B2 (hr) |
| EP (2) | EP2935320B1 (hr) |
| JP (1) | JP6499080B2 (hr) |
| KR (1) | KR102182523B1 (hr) |
| CN (1) | CN105121462B (hr) |
| AP (1) | AP2015008440A0 (hr) |
| AU (1) | AU2013365796B2 (hr) |
| BR (1) | BR112015013708B1 (hr) |
| CA (1) | CA2894976C (hr) |
| CL (1) | CL2015001708A1 (hr) |
| CR (2) | CR20200079A (hr) |
| CU (1) | CU24308B1 (hr) |
| CY (1) | CY1122309T1 (hr) |
| DK (1) | DK2935320T3 (hr) |
| EA (1) | EA034356B1 (hr) |
| EC (1) | ECSP15031046A (hr) |
| ES (1) | ES2756330T3 (hr) |
| GT (1) | GT201500168A (hr) |
| HR (1) | HRP20191965T1 (hr) |
| HU (1) | HUE047386T2 (hr) |
| IL (1) | IL239387A0 (hr) |
| LT (1) | LT2935320T (hr) |
| MA (1) | MA38153B1 (hr) |
| MX (1) | MX363021B (hr) |
| MY (1) | MY174820A (hr) |
| NZ (1) | NZ708091A (hr) |
| PE (2) | PE20200894A1 (hr) |
| PH (1) | PH12015501271A1 (hr) |
| PL (1) | PL2935320T3 (hr) |
| PT (1) | PT2935320T (hr) |
| RS (1) | RS59545B1 (hr) |
| SA (1) | SA515360603B1 (hr) |
| SG (1) | SG11201503782PA (hr) |
| SI (1) | SI2935320T1 (hr) |
| TN (1) | TN2015000182A1 (hr) |
| WO (1) | WO2014097116A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160091888A (ko) * | 2013-10-02 | 2016-08-03 | 노파르티스 아게 | 요법에 사용하기 위한 인슐린-유사 성장 인자 모방체 |
| AU2017228475A1 (en) * | 2016-03-04 | 2018-09-13 | Shire Human Genetic Therapies, Inc. | Recombinant follistatin-Fc fusion proteins and use in treating duchenne muscular dystrophy |
| US10953074B2 (en) * | 2017-01-08 | 2021-03-23 | Richard D. Lippman | Composition and method for improving sensorineural hearing |
| EP3569614A1 (en) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
| TW202019458A (zh) * | 2018-06-27 | 2020-06-01 | 美商裘美娜治療公司 | 肝素相關多肽及其用途 |
| CN109053875B (zh) * | 2018-08-31 | 2021-06-29 | 重庆大学 | 突变型igf-1、重组质粒、重组蛋白及应用 |
| RU2711111C1 (ru) * | 2018-09-05 | 2020-01-15 | Илья Владимирович Духовлинов | Гибридный белок igf-1-long для лечения инсульта, нуклеиновая кислота, вектор, клетка, фармацевтическая композиция, способ лечения |
| CN110642937B (zh) * | 2019-10-11 | 2021-04-06 | 南开大学 | 多肽衍生物、纳米纤维及其应用 |
| US12358963B2 (en) | 2019-12-24 | 2025-07-15 | Juvena Therapeutics, Inc. | Regenerative polypeptides and uses thereof |
| JP2024525213A (ja) | 2021-06-21 | 2024-07-10 | ジュベナ セラピューティクス，インク． | 再生ポリペプチドおよびその使用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| IL143866A0 (en) | 1999-01-06 | 2002-04-21 | Genentech Inc | Insulin-like growth factor (igf) i mutant variants |
| PT1141015E (pt) * | 1999-01-06 | 2009-10-13 | Genentech Inc | Variantes mutantes do factor de crescimento do tipo insulina (igf)i |
| WO2002086075A2 (en) | 2001-04-19 | 2002-10-31 | The Scripps Research Institute | Methods and composition for the production of orthoganal trna-aminoacyltrna synthetase pairs |
| US7355018B2 (en) | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| EP1674113A1 (en) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
| WO2006074390A2 (en) | 2005-01-07 | 2006-07-13 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity with combination therapeautics of igf-i fusion polypeptides |
| US7521211B2 (en) * | 2005-04-05 | 2009-04-21 | Regeneron Pharmaceuticals, Inc | IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof |
| JO2968B1 (en) | 2006-06-09 | 2016-03-15 | نوفارتيس ايه جي | Polypeptides are a stable insulin-like growth factor |
| CN101466398A (zh) * | 2006-06-09 | 2009-06-24 | 诺瓦提斯公司 | 稳定的胰岛素样生长因子多肽 |
| BRPI0821311B1 (pt) | 2007-12-21 | 2018-09-18 | Novartis Ag | Ácido nucleico de vetor linearizado, método para produção de uma célula hospedeira de mamífero compreendendo o referido ácido, e método para produção de um polipetídeode interesse |
| AR076402A1 (es) | 2009-04-27 | 2011-06-08 | Novartis Ag | Composiciones y metodos para aumentar el crecimiento muscular |
| WO2011011073A1 (en) * | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1 |
| WO2011011071A2 (en) | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Analogues of insulin-like growth factor-1 (igf-1) |
| EP2935319B1 (en) | 2012-12-18 | 2019-04-24 | Novartis AG | Production of therapeutic proteins in genetically modified mammalian cells |
| KR20160091888A (ko) | 2013-10-02 | 2016-08-03 | 노파르티스 아게 | 요법에 사용하기 위한 인슐린-유사 성장 인자 모방체 |
| UY35874A (es) | 2013-12-12 | 2015-07-31 | Novartis Ag | Un proceso para la preparación de una composición de proteínas pegiladas |
-
2013
- 2013-12-16 LT LT13828987T patent/LT2935320T/lt unknown
- 2013-12-16 AP AP2015008440A patent/AP2015008440A0/xx unknown
- 2013-12-16 AU AU2013365796A patent/AU2013365796B2/en not_active Ceased
- 2013-12-16 EP EP13828987.1A patent/EP2935320B1/en active Active
- 2013-12-16 CR CR20200079A patent/CR20200079A/es unknown
- 2013-12-16 CU CUP2015000064A patent/CU24308B1/xx unknown
- 2013-12-16 CN CN201380066090.8A patent/CN105121462B/zh active Active
- 2013-12-16 SG SG11201503782PA patent/SG11201503782PA/en unknown
- 2013-12-16 NZ NZ708091A patent/NZ708091A/en not_active IP Right Cessation
- 2013-12-16 EP EP19191570.1A patent/EP3626735A1/en not_active Withdrawn
- 2013-12-16 PL PL13828987T patent/PL2935320T3/pl unknown
- 2013-12-16 MA MA38153A patent/MA38153B1/fr unknown
- 2013-12-16 RS RS20191416A patent/RS59545B1/sr unknown
- 2013-12-16 PE PE2019002049A patent/PE20200894A1/es unknown
- 2013-12-16 ES ES13828987T patent/ES2756330T3/es active Active
- 2013-12-16 CA CA2894976A patent/CA2894976C/en active Active
- 2013-12-16 PT PT138289871T patent/PT2935320T/pt unknown
- 2013-12-16 PE PE2015001039A patent/PE20151612A1/es not_active Application Discontinuation
- 2013-12-16 JP JP2015547255A patent/JP6499080B2/ja active Active
- 2013-12-16 MY MYPI2015001207A patent/MY174820A/en unknown
- 2013-12-16 KR KR1020157018991A patent/KR102182523B1/ko active Active
- 2013-12-16 MX MX2015007932A patent/MX363021B/es unknown
- 2013-12-16 SI SI201331611T patent/SI2935320T1/sl unknown
- 2013-12-16 DK DK13828987T patent/DK2935320T3/da active
- 2013-12-16 EA EA201591165A patent/EA034356B1/ru not_active IP Right Cessation
- 2013-12-16 HR HRP20191965TT patent/HRP20191965T1/hr unknown
- 2013-12-16 BR BR112015013708-3A patent/BR112015013708B1/pt not_active IP Right Cessation
- 2013-12-16 HU HUE13828987A patent/HUE047386T2/hu unknown
- 2013-12-16 US US14/651,686 patent/US10167329B2/en active Active
- 2013-12-16 WO PCT/IB2013/060985 patent/WO2014097116A1/en active Application Filing
-
2015
- 2015-05-08 TN TNP2015000182A patent/TN2015000182A1/fr unknown
- 2015-06-04 PH PH12015501271A patent/PH12015501271A1/en unknown
- 2015-06-11 IL IL239387A patent/IL239387A0/en active IP Right Grant
- 2015-06-17 CL CL2015001708A patent/CL2015001708A1/es unknown
- 2015-06-17 SA SA515360603A patent/SA515360603B1/ar unknown
- 2015-06-18 GT GT201500168A patent/GT201500168A/es unknown
- 2015-06-18 CR CR20150324A patent/CR20150324A/es unknown
- 2015-07-17 EC ECIEPI201531046A patent/ECSP15031046A/es unknown
-
2019
- 2019-11-19 CY CY20191101212T patent/CY1122309T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191965T1 (hr) | Stabilizirani polipeptidi faktora rasta slični inzulinu | |
| AR072009A1 (es) | Mutantes del factor de crecimiento de los fibroblastos fgf21 y usos de los mismos | |
| EA201890220A1 (ru) | Вакцина против rsv | |
| MX2020010806A (es) | Peptidos anti-inflamatorios y usos de los mismos. | |
| SA518390954B1 (ar) | لقاحات علاجية لفيروس الورم الحليمي البشري 18 | |
| HRP20240135T1 (hr) | Fgf21 mutanti i njihove upotrebe | |
| FI3256579T3 (fi) | Kysteiiniproteaasi | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| JP2016500250A5 (hr) | ||
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| BRPI0606301A2 (pt) | processo para fabricar uma mistura de sais de acetato de polipeptìdeos, processo para fabricar uma mistura de sais de polipeptìdeos de trifluoroacetila não protegidos, mistura de sais de acetato de polipeptìdeos, composição farmacêutica, processos para a preparação de uma composição farmacêutica, e, mistura de polipeptìdeos de trifluoroacetila protegidos | |
| JP2011526886A5 (hr) | ||
| NZ630484A (en) | Compositions and methods for treatment of metabolic disorders and diseases | |
| NZ628987A (en) | Extended recombinant polypeptides and compositions comprising same | |
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| JP2020507623A5 (hr) | ||
| MX2022002476A (es) | Peptido q-er. | |
| EP4306123A3 (en) | Saposin-a derived peptides and uses thereof | |
| EP2589658A4 (en) | PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN | |
| BR112013019513A2 (pt) | métodos para o tratamento de úlceras diabéticas do pé | |
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| HRP20241279T1 (hr) | Pripravak koji sadrži probiotike koji prekomjerno eksprimiraju protein clpb za uporabu u liječenju pretilosti | |
| RU2015103816A (ru) | ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E | |
| WO2012174397A3 (en) | Anti-inflammatory pharmaceutical products | |
| JP2017505772A5 (hr) |